

Paul L Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9225061/publications.pdf>

Version: 2024-02-01

351
papers

11,014
citations

36691

53
h-index

56606

87
g-index

351
all docs

351
docs citations

351
times ranked

12589
citing authors

#	ARTICLE	IF	CITATIONS
1	Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 309-316.	2.0	8
2	Boosting the Abscopal Effect Using Immunogenic Biomaterials With Varying Radiation Therapy Field Sizes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 475-486.	0.4	13
3	Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 75-82.	0.4	34
4	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. <i>JCO Oncology Practice</i> , 2022, 18, e204-e218.	1.4	18
5	Body fat composition as biomarker for clinical outcomes and treatment tolerance in high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 159-159.	0.8	0
6	Racial disparities in treatment delay among younger men with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 590-592.	2.0	8
7	Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy. <i>Prostate</i> , 2022, 82, 1098-1106.	1.2	2
8	Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 720-727.	0.8	10
9	Psychological Distress and Access to Mental Health Services Among Cancer Survivors: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021, 36, 3243-3245.	1.3	6
10	Mental Distress and Mental Health Services Receipt in Foreign-Born Survivors of Cancer: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021, 36, 2495-2498.	1.3	1
11	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	0.9	140
12	Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 168-172.	0.6	2
13	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 719-726.	3.0	45
14	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
15	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 130.e17-130.e24.	0.8	4
16	The Case for Brachytherapy: Why It Deserves a Renaissance. <i>Advances in Radiation Oncology</i> , 2021, 6, 100605.	0.6	10
17	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?. <i>Practical Radiation Oncology</i> , 2021, 11, e426-e433.	1.1	3
18	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 953-963.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. <i>Brachytherapy</i> , 2021, 20, 1-9.	0.2	0
20	Disparities in Mortality from Larynx Cancer: Implications for Reducing Racial Differences. <i>Laryngoscope</i> , 2021, 131, E1147-E1155.	1.1	8
21	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	2.6	3
22	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. <i>European Urology Oncology</i> , 2021, 4, 66-72.	2.6	20
23	Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. <i>JCO Oncology Practice</i> , 2021, 17, e1489-e1501.	1.4	13
24	Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 205-205.	0.8	0
25	Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 121-121.	0.8	0
26	Association between travel distance and use of postoperative radiation therapy among men with organ-confined prostate cancer: Does geography influence treatment decisions?. <i>Journal of Clinical Oncology</i> , 2021, 39, 24-24.	0.8	1
27	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	2.8	4
28	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
29	Correlative analysis between two commercially available post-prostatectomy genomic tests. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 575-577.	2.0	0
30	Financial worry and psychological distress among cancer survivors in the United States, 2013-2018. <i>Supportive Care in Cancer</i> , 2021, 29, 5523-5535.	1.0	25
31	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	3.4	82
32	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. <i>Cancer</i> , 2021, 127, 2213-2221.	2.0	9
33	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1279-1285.	0.4	18
34	Association of Medicaid expansion and insurance status, cancer stage, treatment and mortality among patients with cervical cancer. <i>Cancer Reports</i> , 2021, 4, e1407.	0.6	8
35	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	2.0	50
36	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. <i>Radiotherapy and Oncology</i> , 2021, 161, 241-250.	0.3	7

#	ARTICLE	IF	CITATIONS
37	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214.	0.5	3
38	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021, 258-259, 61-68.	0.2	2
39	Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 414-422.	2.0	9
40	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	9
41	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	2.8	16
42	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	0.9	18
43	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. <i>Journal of the National Cancer Institute</i> , 2020, 112, 229-237.	3.0	15
44	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 179-183.	2.0	12
45	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	0.9	37
46	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020, 126, 1407-1412.	2.0	8
47	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 163-167.	0.6	19
48	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 410-418.	2.0	17
49	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , 2020, 126, 717-724.	2.0	64
50	Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. <i>N Engl J Med</i> 2020;382:2187-96. <i>European Urology</i> , 2020, 78, e195.	0.9	0
51	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
52	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
53	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e9-735.e15.	0.8	2
54	Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. <i>Prostate</i> , 2020, 80, 1128-1133.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. <i>Urology</i> , 2020, 145, 197-203.	0.5	1
56	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1630.	3.4	25
57	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 246-254.e5.	0.9	9
58	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 1793.	3.4	10
59	Less Is More During COVID 19. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 339.	0.4	1
60	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , 2020, 3, e201839.	2.8	37
61	Prostate cancer management costs vary by disease stage at presentation. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 564-566.	2.0	2
62	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	0.8	26
63	To Radiate or Not to Radiateâ€”The Challenges of Pelvic Reirradiation. <i>Seminars in Radiation Oncology</i> , 2020, 30, 238-241.	1.0	3
64	Local management of preinvasive and clinical T1-3 penile cancer: utilization of diverse treatment modalities. <i>Future Oncology</i> , 2020, 16, 955-960.	1.1	5
65	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
66	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 936-940.	0.4	3
67	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58
68	Changes in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019. <i>JAMA Network Open</i> , 2020, 3, e200841.	2.8	18
69	Validation of a subclassification for high-risk prostate cancer in a prospective cohort. <i>Cancer</i> , 2020, 126, 2132-2138.	2.0	7
70	Intermediate-risk Prostate Cancer: Stratification and Management. <i>European Urology Oncology</i> , 2020, 3, 270-280.	2.6	51
71	Surgical management versus combination radiotherapy in Gleason score 9-10 prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 135-135.	0.8	1
72	Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 24-24.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.. Journal of Clinical Oncology, 2020, 38, 276-276.	0.8	9
74	INTREPId (INTErmediate Risk EreCtion Preservation Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS384-TPS384.	0.8	1
75	Doublecortin expression in prostate adenocarcinoma and neuroendocrine tumors.. Journal of Clinical Oncology, 2020, 38, 161-161.	0.8	0
76	Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests.. Journal of Clinical Oncology, 2020, 38, 348-348.	0.8	1
77	Characteristics of radiation-associated bladder cancer compared to primary bladder cancer. Journal of Clinical Oncology, 2020, 38, 582-582.	0.8	2
78	Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.. Journal of Clinical Oncology, 2020, 38, 337-337.	0.8	0
79	Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, 295-295.	0.8	0
80	Mental distress and mental health services receipt in foreign-born survivors of cancer: A national health interview survey analysis.. Journal of Clinical Oncology, 2020, 38, e19001-e19001.	0.8	1
81	Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer.. Journal of Clinical Oncology, 2020, 38, 101-101.	0.8	1
82	Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clinical Infectious Diseases, 2019, 68, 247-255.	2.9	42
83	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer, 2019, 125, 3338-3346.	2.0	15
84	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 621-627.	0.4	10
85	Definitive and sustained increase in prostate cancer metastases in the United States. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 988-990.	0.8	7
86	Readdressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU International, 2019, 124, 35-39.	1.3	4
87	Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. European Urology, 2019, 75, 1038-1040.	0.9	38
88	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	3.4	288
89	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2019, 104, 778-789.	0.4	247
90	Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. Journal of the American College of Cardiology, 2019, 73, 2976-2987.	1.2	163

#	ARTICLE	IF	CITATIONS
91	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019, 125, 3164-3171.	2.0	35
92	Association of Treatment With 5 α -Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. <i>JAMA Internal Medicine</i> , 2019, 179, 812.	2.6	44
93	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , 2019, 25, 4290-4299.	3.2	38
94	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 575.e9-575.e18.	0.8	5
95	Evolution of Radiation Oncology in Pakistan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 11-16.	0.4	5
96	A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e472-e481.	0.9	5
97	Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 704.	3.8	168
98	Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. <i>European Urology Oncology</i> , 2019, 2, 189-195.	2.6	10
99	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 265-273.	2.6	75
100	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019, 2, 405-412.	2.6	14
101	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 125-136.	2.0	53
102	Reply to Partial gland therapy for prostate cancer. <i>Cancer</i> , 2019, 125, 819-820.	2.0	0
103	Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review. <i>European Urology</i> , 2019, 75, 464-476.	0.9	65
104	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.	3.2	52
105	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , 2019, 26, 297-305.	0.7	20
106	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019, 125, 1319-1329.	2.0	20
107	Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. <i>Brachytherapy</i> , 2019, 18, 198-203.	0.2	1
108	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019, 18, 186-191.	0.2	18

#	ARTICLE	IF	CITATIONS
109	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	0.9	18
110	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	3.0	142
111	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 69-76.	1.6	40
112	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , 2019, 5, 474-481.	1.6	44
113	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019, 201, 735-741.	0.2	31
114	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. <i>Journal of Urology</i> , 2019, 201, 728-734.	0.2	4
115	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 973-978.	0.2	24
116	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.. <i>Journal of Clinical Oncology</i> , 2019, 37, 12-12.	0.8	1
117	Genomic validation of three-tiered sub-classification of high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 17-17.	0.8	1
118	External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 21-21.	0.8	1
119	Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS349-TPS349.	0.8	3
120	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1049-1058.	2.3	21
121	Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 44-44.	0.8	0
122	Active surveillance and watchful waiting for low-risk prostate cancer in black patients: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10-10.	0.8	0
123	Management Migration in United States patients diagnosed with localized prostate cancer from 2010-2015.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11-11.	0.8	0
124	Practice Patterns and Outcomes Among Patients With NOM0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 941-948.	2.3	0
125	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	3.8	252
126	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018, 74, 146-154.	0.9	72

#	ARTICLE	IF	CITATIONS
127	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2018, 200, 573-581.	0.2	31
128	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermannsâ€™ Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262â€“70.. <i>European Urology</i> , 2018, 73, e96-e97.	0.9	0
129	Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis. <i>Urology</i> , 2018, 114, 155-162.	0.5	18
130	Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 157.e15-157.e20.	0.8	6
131	Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. <i>Journal of Urology</i> , 2018, 199, 1510-1517.	0.2	31
132	Threeâ€™month posttreatment prostateâ€™specific antigen level as a biomarker of treatment response in patients with intermediateâ€™risk or highâ€™risk prostate cancer treated with androgen deprivation therapy and radiotherapy. <i>Cancer</i> , 2018, 124, 2939-2947.	2.0	15
133	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018, 131, 517-523.	0.6	13
134	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.4	7
135	Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 409-415.	0.6	52
136	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. <i>European Urology</i> , 2018, 73, 11-20.	0.9	76
137	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , 2018, 73, 262-270.	0.9	20
138	A novel approach to an automated needle insertion in brachytherapy procedures. <i>Medical and Biological Engineering and Computing</i> , 2018, 56, 273-287.	1.6	9
139	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	0.9	55
140	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 953-959.	0.6	14
141	Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. <i>Cancer</i> , 2018, 124, 752-759.	2.0	23
142	Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 307-317.e1.	0.6	26
143	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 225.	3.4	58
144	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. <i>European Urology</i> , 2018, 73, 452-461.	0.9	46

#	ARTICLE	IF	CITATIONS
145	Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 53-58.	0.4	9
146	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , 2018, 124, 55-64.	2.0	40
147	Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. <i>Journal of Surgical Education</i> , 2018, 75, 434-441.	1.2	2
148	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	0.9	54
149	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018, 124, 1141-1149.	2.0	21
150	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e100-e101.	0.9	1
151	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 226-234.	0.9	14
152	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , 2018, 73, 445-451.	0.9	43
153	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4027-4034.	0.7	21
154	Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E1185-E1193.	1.8	24
155	Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. <i>Journal of the Endocrine Society</i> , 2018, 2, 485-496.	0.1	33
156	Welcome to <i>European Urology Oncology</i> : Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. <i>European Urology Oncology</i> , 2018, 1, 1-2.	2.6	3
157	Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 34-43.	0.4	9
158	Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. <i>Cancer</i> , 2018, 124, 3528-3535.	2.0	15
159	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.4	10
160	In Reply to Ong et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1295.	0.4	0
161	Reply to John T. Leppert and James D. Brooks's Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>Eur Urol</i> 2018;74:146-54. <i>European Urology</i> , 2018, 74, e112-e113.	0.9	1
162	Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 313-317.	0.9	18

#	ARTICLE	IF	CITATIONS
163	Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 3-18.	2.6	10
164	Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths?. <i>Journal of Clinical Oncology</i> , 2018, 36, 130-130.	0.8	5
165	Long-term outcomes of magnetic resonance image-guided partial prostate brachytherapy for favorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 138-138.	0.8	1
166	Practice patterns and outcomes among patients with NOMO prostate cancer and a very high prostate-specific antigen.. <i>Journal of Clinical Oncology</i> , 2018, 36, 48-48.	0.8	0
167	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 78-78.	0.8	0
168	Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 72-72.	0.8	0
169	Contemporary trends in abiraterone and enzalutamide prescription by provider specialty.. <i>Journal of Clinical Oncology</i> , 2018, 36, 366-366.	0.8	1
170	Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification.. <i>Journal of Clinical Oncology</i> , 2018, 36, 39-39.	0.8	0
171	Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 23-23.	0.8	0
172	Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102.	0.8	0
173	Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 59-59.	0.8	0
174	Laboratory eligibility criteria as potential barriers to participation by black men in prostate cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 73-73.	0.8	1
175	Prostate Cancer â€œ Local Treatment after Radiorecurrence: Surgery - Back to the future?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 433-434.	0.7	1
176	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 563-569.e3.	0.9	7
177	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 726-732.	0.4	11
178	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017, 72, 483-487.	0.9	110
179	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
180	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 55.	1.0	15

#	ARTICLE	IF	CITATIONS
181	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e25-542.e32.	0.8	6
182	Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. <i>European Urology</i> , 2017, 72, 712-735.	0.9	79
183	Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. <i>Advances in Radiation Oncology</i> , 2017, 2, 140-147.	0.6	7
184	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 338-343.	0.4	9
185	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. <i>Advances in Radiation Oncology</i> , 2017, 2, 437-454.	0.6	21
186	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2017, 16, 266-276.	0.2	26
187	Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. <i>Cancer</i> , 2017, 123, 4832-4840.	2.0	20
188	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. <i>Journal of Urology</i> , 2017, 198, 1295-1300.	0.2	10
189	Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. <i>Prostate International</i> , 2017, 5, 89-94.	1.2	3
190	Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. <i>International Journal of Urology</i> , 2017, 24, 743-748.	0.5	34
191	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 904-911.	0.4	6
192	Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 664.e1-664.e9.	0.8	73
193	Approach to the Patient with High-Risk Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 635-645.	0.8	6
194	The evolution of brachytherapy for prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 415-439.	1.9	106
195	Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 76-85.	0.8	21
196	Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. <i>Journal of Urology</i> , 2017, 197, 363-368.	0.2	20
197	Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 1194-1201.	0.8	37
198	ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. <i>Advances in Radiation Oncology</i> , 2017, 2, 62-84.	0.6	30

#	ARTICLE	IF	CITATIONS
199	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 35, 3-3.	0.8	2
200	Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.. Journal of Clinical Oncology, 2017, 2017, 4-4.	0.8	1
201	National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 50-50.	0.8	0
202	Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.. Journal of Clinical Oncology, 2017, 35, e545-e545.	0.8	0
203	The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients.. Journal of Clinical Oncology, 2017, 35, 19-19.	0.8	1
204	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. Journal of Clinical Oncology, 2017, 35, 18-18.	0.8	0
205	Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis.. Journal of Clinical Oncology, 2017, 35, 164-164.	0.8	1
206	Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review.. Journal of Clinical Oncology, 2017, 35, 150-150.	0.8	1
207	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 2017, 3-3.	0.8	0
208	Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis.. Journal of Clinical Oncology, 2017, 35, 529-529.	0.8	1
209	Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.. Journal of Clinical Oncology, 2017, 35, 4-4.	0.8	1
210	Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients.. Journal of Clinical Oncology, 2017, 35, 5080-5080.	0.8	1
211	Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. Journal of Contemporary Brachytherapy, 2016, 1, 1-6.	0.4	23
212	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
213	Suicide and accidental deaths among patients with non-metastatic prostate cancer. BJU International, 2016, 118, 286-297.	1.3	39
214	Data on Medicare eligibility and cancer screening utilization. Data in Brief, 2016, 7, 679-681.	0.5	4
215	Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?. International Journal of Radiation Oncology Biology Physics, 2016, 96, 313-317.	0.4	51
216	Asian Americans and prostate cancer: A nationwide population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e7-233.e15.	0.8	34

#	ARTICLE	IF	CITATIONS
217	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1905-1912.	0.8	121
218	Value of Extra-Early Initiation of Salvage Radiation for Increasing Prostate-Specific Antigen After Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3597-3599.	0.8	4
219	Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 624-628.	0.4	48
220	Determinants of cancer screening in Asian-Americans. <i>Cancer Causes and Control</i> , 2016, 27, 989-998.	0.8	33
221	Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. <i>Cancer</i> , 2016, 122, 78-83.	2.0	41
222	Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 305-311.	0.5	10
223	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016, 15, 695-700.	0.2	13
224	The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. <i>Brachytherapy</i> , 2016, 15, 701-706.	0.2	37
225	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016, 122, 3371-3377.	2.0	27
226	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	5.1	182
227	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 421-428.	2.3	10
228	Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2016, 122, 2496-2504.	2.0	63
229	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3267-3275.	0.8	185
230	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. <i>Preventive Medicine</i> , 2016, 89, 140-145.	1.6	63
231	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016, 2, 532-539.	1.6	23
232	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 683-690.	0.4	57
233	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2016, 196, 1090-1095.	0.2	42
234	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536.	0.8	70

#	ARTICLE	IF	CITATIONS
235	Recent relocation and decreased survival following a cancer diagnosis. Preventive Medicine, 2016, 89, 245-250.	1.6	7
236	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer, 2016, 122, 1505-1512.	2.0	27
237	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	0.9	11
238	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 471.	3.4	46
239	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clinical Cancer Research, 2016, 22, 1777-1786.	3.2	42
240	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	0.8	17
241	ACR Appropriateness Criteria Renal Cell Carcinoma Staging. Journal of the American College of Radiology, 2016, 13, 518-525.	0.9	32
242	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. Journal of Urology, 2016, 195, 913-918.	0.2	32
243	Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2016, 94, 440-449.	0.4	23
244	The impact of Medicare eligibility on cancer screening behaviors. Preventive Medicine, 2016, 85, 47-52.	1.6	19
245	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with $\geq 50\%$ Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	0.5	16
246	High-Dose-Rate Monotherapy for Localized Prostate Cancer—What More Will It Take to Make This a Standard Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 94, 655-656.	0.4	5
247	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	3.4	94
248	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	1.3	45
249	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
250	Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 2016, 117, E20-8.	1.3	22
251	Development and validation of genomic signature to predict ADT treatment failure.. Journal of Clinical Oncology, 2016, 34, 5018-5018.	0.8	1
252	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).. Journal of Clinical Oncology, 2016, 34, TPS5086-TPS5086.	0.8	1

#	ARTICLE	IF	CITATIONS
253	NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 1-1.	0.8	14
254	Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.. Journal of Clinical Oncology, 2016, 34, 106-106.	0.8	0
255	Re-irradiation of the pelvis for a genitourinary second malignant neoplasm or a local recurrence after full-dose pelvic radiotherapy for a pelvic cancer: Experience in a high-volume cancer center.. Journal of Clinical Oncology, 2016, 34, 494-494.	0.8	0
256	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 54-54.	0.8	0
257	Socioeconomic disparities in the receipt of radiation for node-positive prostate cancer.. Journal of Clinical Oncology, 2016, 34, 53-53.	0.8	0
258	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report.. Journal of Clinical Oncology, 2016, 34, 450-450.	0.8	0
259	Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 52-52.	0.8	0
260	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.. Journal of Clinical Oncology, 2016, 34, 33-33.	0.8	0
261	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2016, 34, 442-442.	0.8	0
262	The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population.. Journal of Clinical Oncology, 2016, 34, 304-304.	0.8	0
263	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	2.3	37
264	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	2.3	72
265	A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiation Oncology, 2015, 10, 243.	1.2	8
266	An evaluation of the "weekend effect"™ in patients admitted with metastatic prostate cancer. BJU International, 2015, 116, 911-919.	1.3	8
267	Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. Radiation Oncology, 2015, 10, 155.	1.2	20
268	Population-based assessment of determining predictors for quality of prostate cancer surveillance. Cancer, 2015, 121, 4150-4157.	2.0	24
269	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	0.6	21
270	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. European Urology, 2015, 68, 32-39.	0.9	43

#	ARTICLE	IF	CITATIONS
271	Shared Decision Making and Use of Decision Aids for Localized Prostate Cancer. <i>JAMA Internal Medicine</i> , 2015, 175, 792.	2.6	43
272	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2015, 14, 511-516.	0.2	4
273	Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2015, 14, 773-780.	0.2	21
274	Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e1-e6.	0.9	19
275	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 257-276.	2.0	37
276	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	0.5	21
277	Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. <i>Journal of Urology</i> , 2015, 193, 820-825.	0.2	40
278	Potential for Information and Communication Technologies to Catalyze Global Collaborations in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 444-447.	0.4	20
279	Brachytherapy Application With In Situ Dose Painting Administered by Gold Nanoparticle Eluters. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 385-392.	0.4	37
280	GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 370-377.e1.	0.9	8
281	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 251-263.	2.0	8
282	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 330.e19-330.e25.	0.8	13
283	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 525-530.e3.	0.9	23
284	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv054-djv054.	3.0	63
285	Androgen Deprivation Therapy Reversibly Increases Endothelium-Dependent Vasodilation in Men With Prostate Cancer. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	20
286	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 343-349.	0.2	109
287	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 228-237.	2.0	111
288	National Trends in the Recommendation of Radiotherapy After Prostatectomy for Prostate Cancer Before and After the Reporting of a Survival Benefit in March 2009. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e167-e172.	0.9	13

#	ARTICLE	IF	CITATIONS
289	Brachytherapy: Where Has It Gone?. <i>Journal of Clinical Oncology</i> , 2015, 33, 980-982.	0.8	102
290	Toward Personalizing the Use of Androgen Deprivation Therapy to Maximize Benefit and Minimize Harm. <i>European Urology</i> , 2015, 68, 397-398.	0.9	2
291	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 503.e7-503.e15.	0.8	9
292	Definition and Validation of "Favorable High-Risk Prostate Cancer" Implications for Personalizing Treatment of Radiation-Managed Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 828-835.	0.4	40
293	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 504.e9-504.e17.	0.8	21
294	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2077.	3.8	105
295	Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. <i>BJU International</i> , 2015, 116, 358-365.	1.3	66
296	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 17.e9-17.e18.	0.8	24
297	Income inequality and treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e7-18.e13.	0.8	53
298	Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. <i>Radiation Oncology</i> , 2014, 9, 200.	1.2	12
299	Independent brachytherapy plan verification software: Improving efficacy and efficiency. <i>Radiotherapy and Oncology</i> , 2014, 113, 420-424.	0.3	23
300	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. <i>Journal of Clinical Oncology</i> , 2014, 32, 2025-2030.	0.8	112
301	Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators. <i>Prostate Cancer</i> , 2014, 2014, 1-6.	0.4	5
302	Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 756-764.	0.4	71
303	The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 732-751.	0.9	298
304	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. <i>European Urology</i> , 2014, 66, 1125-1132.	0.9	29
305	Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States. <i>Journal of Urology</i> , 2014, 192, 1650-1656.	0.2	37
306	Mental health outcomes in elderly men with prostate cancer: Equal contribution. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1333-1340.	0.8	59

#	ARTICLE	IF	CITATIONS
307	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. <i>Urology</i> , 2014, 84, 386-392.	0.5	86
308	Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: Implications for the use of newer isotopes. <i>Brachytherapy</i> , 2014, 13, 152-156.	0.2	8
309	ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2014, 13, 27-31.	0.2	24
310	Androgen-deprivation Therapy and Cardiovascular Harm: Let's Not Throw Out the Baby with the Bathwater. <i>European Urology</i> , 2014, 65, 710-712.	0.9	11
311	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. <i>Journal of Urology</i> , 2014, 191, 1678-1684.	0.2	19
312	Racial Disparities in Prostate Cancerâ€™Specific Mortality in Men With Low-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e189-e195.	0.9	46
313	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. <i>Urology</i> , 2014, 83, 1316-1321.	0.5	17
314	Population-based Comparative Effectiveness of Salvage Radical Prostatectomy vs Cryotherapy. <i>Urology</i> , 2014, 83, 653-657.	0.5	11
315	Placement of empty catheters for an HDR-Emulating LDR Prostate Brachytherapy technique: Comparison to standard intraoperative planning. <i>Brachytherapy</i> , 2014, 13, 375-379.	0.2	4
316	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. <i>European Urology</i> , 2014, 66, 666-672.	0.9	97
317	Hydrogel Spacing for Radiotherapy of Prostate Cancer: A Review of the Literature. <i>Urology Practice</i> , 2014, 1, 79-85.	0.2	8
318	Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 303-308.	0.8	22
319	Adrenocortical carcinoma: The management of metastatic disease. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 123-132.	2.0	43
320	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 352-358.	0.5	21
321	Response to Drs Rogers, Hayes, and Demanes. <i>Brachytherapy</i> , 2014, 13, 523-525.	0.2	0
322	Perceptions of Radiation Oncologists and Urologists on Sources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 277-283.	0.4	3
323	Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. <i>Brachytherapy</i> , 2014, 13, 442-449.	0.2	38
324	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1285-1291.	0.8	81

#	ARTICLE	IF	CITATIONS
325	High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: Case report and review of the literature. <i>Brachytherapy</i> , 2013, 12, 77-83.	0.2	25
326	PSA screening: the case in favor. <i>Oncology</i> , 2013, 27, 980, 982.	0.4	0
327	Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1411-1416.	0.4	67
328	Harms versus benefits with duration of androgen suppression. <i>Lancet Oncology</i> , The, 2012, 13, 1182-1183.	5.1	1
329	Updated Results of Magnetic Resonance Imaging Guided Partial Prostate Brachytherapy for Favorable Risk Prostate Cancer: Implications for Focal Therapy. <i>Journal of Urology</i> , 2012, 188, 1151-1156.	0.2	86
330	Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. <i>Practical Radiation Oncology</i> , 2012, 2, 172-178.	1.1	1
331	Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. <i>BJU International</i> , 2012, 110, 201-205.	1.3	19
332	The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 302-308.	0.8	18
333	Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. <i>Cancer</i> , 2011, 117, 406-413.	2.0	28
334	Risk of All-Cause and Prostate Cancer-Specific Mortality After Brachytherapy in Men With Small Prostate Size. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1318-1322.	0.4	11
335	Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1517-1524.	0.8	291
336	Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2359-66.	3.8	377
337	Rectal Dose-Volume Histogram Parameters Are Associated With Long-Term Patient-Reported Gastrointestinal Quality of Life After Conventional and High-Dose Radiation for Prostate Cancer: A Subgroup Analysis of a Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1081-1085.	0.4	38
338	Comorbidity, body mass index, and age and the risk of nonprostate-specific mortality after a postradiation prostate-specific antigen recurrence. <i>Cancer</i> , 2010, 116, 610-615.	2.0	11
339	Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 337-341.	0.4	17
340	Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1046-1052.	0.4	42
341	Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival. <i>Journal of Clinical Oncology</i> , 2010, 28, 3958-3964.	0.8	113
342	Deciding which patients to treat with salvage radiotherapy after prostatectomy. <i>Oncology</i> , 2010, 24, 705, 711.	0.4	0

#	ARTICLE	IF	CITATIONS
343	Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer. <i>Cancer</i> , 2008, 113, 3146-3152.	2.0	12
344	Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer?. <i>Oncology</i> , 2008, 22, 748-54; discussion 754, 757.	0.4	11
345	High-Dose External Beam Radiation for Localized Prostate Cancer: Current Status and Future Challenges. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 295-301.	1.0	15
346	Effect of Definition of Preradiotherapy Prostate-Specific Antigen Velocity on Its Association with Prostate Cancer-Specific Mortality and All-Cause Mortality. <i>Urology</i> , 2007, 70, 288-293.	0.5	5
347	Magnetic resonance imageâ€guided salvage brachytherapy after radiation in select men who initially presented with favorableâ€risk prostate cancer. <i>Cancer</i> , 2007, 110, 1485-1492.	2.0	136
348	Patient selection, cancer control, and complications after salvage local therapy for postradiation prostateâ€specific antigen failure. <i>Cancer</i> , 2007, 110, 1417-1428.	2.0	237
349	The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. <i>Cancer</i> , 2005, 103, 2053-2059.	2.0	53
350	Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 400-405.	0.4	27
351	The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 295-299.	0.8	49